Tiziana Life Sciences (TLSA)

Its lead candidate is foralumab, also known as TZLS-401, a fully human anti-CD3 monoclonal antibody being studied for central nervous system disorders. Tiziana is developing foralumab with an intranasal delivery approach, which is intended to modulate immune activity without relying on systemic administration. The company’s main area of focus is non-active secondary progressive multiple sclerosis, a form of MS where disability can worsen even when inflammatory relapses are limited or absent.

Tiziana’s broader pipeline also includes programs or exploratory work in conditions such as Alzheimer’s disease, amyotrophic lateral sclerosis, and multiple system atrophy. These are difficult disease areas with large unmet medical needs and limited treatment options, making the scientific opportunity significant but also high risk. Success depends on demonstrating safety, biological activity, and meaningful clinical benefit in carefully designed studies.

For investors, Tiziana represents a biotechnology development story rather than a revenue-driven operating company. Its milestones are likely to revolve around trial enrollment, clinical data, regulatory interactions, and financing capacity. The company is distinctive for its focus on immune modulation in neurological disease, particularly the attempt to apply anti-CD3 therapy to CNS indications through a non-invasive nasal route.